Combination of a Novel HDAC 6 Inhibitor ACY-241 and Anti-PD-L1 Antibody Enhances Anti-Tumor Immunity and Cytotoxicity in Multiple Myeloma

Documenti analoghi

• Histone deacetylase (HDAC) inhibitor ACY241 enhances anti-tumor activities of antigen-specific central memory cytotoxic T lymphocytes against multiple myeloma and solid tumors
  di: Bae, Jooeun, et al.
  Pubblicazione: (2018)
• Targeting tryptophan catabolic kynurenine pathway enhances antitumor immunity and cytotoxicity in multiple myeloma
  di: Ray, Arghya, et al.
  Pubblicazione: (2019)
• Synergistic Anti-Myeloma Activity of the Proteasome Inhibitor Marizomib and the IMiD(®) Immunomodulatory Drug Pomalidomide
  di: Das, Deepika Sharma, et al.
  Pubblicazione: (2015)
• A Novel Alkylating Agent Melflufen Induces Irreversible DNA Damage and Cytotoxicity in Multiple Myeloma Cells
  di: Ray, Arghya, et al.
  Pubblicazione: (2016)
• Blockade of ubiquitin receptor Rpn13 in plasmacytoid dendritic cells triggers anti-myeloma immunity
  di: Ray, Arghya, et al.
  Pubblicazione: (2019)